Clinical trials
Granulomatosis with Polyangiitis trials in the United Kingdom
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
19 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 2 |
| 2007 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 4 |
| 2015 | 1 |
| 2019 | 3 |
| 2020 | 1 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 8 |
| Unknown status | 6 |
| Terminated | 3 |
| Active, not recruiting | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cambridge University Hospitals NHS Foundation Trust | 3 |
| Novartis Pharmaceuticals | 2 |
| University of Oxford | 2 |
| Charite University, Berlin, Germany | 1 |
| Guy's and St Thomas' NHS Foundation Trust | 1 |
| Hoffmann-La Roche | 1 |
| Human Genome Sciences Inc., a GSK Company | 1 |
| Imperial College London | 1 |
| InflaRx GmbH | 1 |
| Nippon Kayaku Co., Ltd. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Granulomatosis with Polyangiitis | 19 |
| Microscopic Polyangiitis | 15 |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 10 |
| Vasculitis | 10 |
| Churg-Strauss Syndrome | 6 |
| Systemic Vasculitis | 4 |
| Polyarteritis Nodosa | 2 |
| Takayasu Arteritis | 2 |
| Autoimmune Diseases | 1 |
| Giant Cell Arteritis | 1 |
Trials
Showing 1 to 19 of 19. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.